Ken Griffin Contrafect Corp Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.09 - $0.19 $27,278 - $57,588	-303,095 Reduced 80.13%	75,164 $7,000
Q3 2022 Nov 14, 2022	BUY	$0.18 - $3.51 $68,086 - $1.33 Million	378,259 New	378,259 $64,000
Q1 2022 May 16, 2022	SELL	$2.26 - $3.84 $54,156 - $92,017	-23,963 Reduced 61.65%	14,904 $54,000
Q4 2021 Feb 14, 2022	SELL	$2.47 - $4.14 $74,497 - $124,866	-30,161 Reduced 43.69%	38,867 $102,000
Q3 2021 Nov 15, 2021	SELL	$3.19 - $4.43 $7,324 - $10,171	-2,296 Reduced 3.22%	69,028 $280,000
Q2 2021 Aug 16, 2021	BUY	$3.58 - $4.9 $105,971 - $145,044	29,601 Added 70.95%	71,324 $313,000
Q1 2021 May 17, 2021	BUY	$4.46 - $6.68 $65,557 - $98,189	14,699 Added 54.39%	41,723 $200,000
Q4 2020 Feb 16, 2021	BUY	$5.05 - $6.4 $74,901 - $94,924	14,832 Added 121.65%	27,024 $137,000
Q3 2020 Nov 16, 2020	SELL	$5.05 - $6.99 $3,989 - $5,522	-790 Reduced 6.09%	12,192 $64,000
Q2 2020 Aug 14, 2020	BUY	$4.69 - $7.81 $60,885 - $101,389	12,982 New	12,982 $83,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.